You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Patritumab deruxtecan

Showing 1 - 25 of 78
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Metastases, Adult Trial in Durham (Patritumab deruxtecan)

Not yet recruiting
  • Brain Metastases, Adult
  • Patritumab deruxtecan
  • Durham, North Carolina
    Duke University Medical Center
Jan 19, 2023

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)

Available
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
  • (no location specified)
Oct 17, 2023

NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Santa Monica, California
  • +13 more
Feb 1, 2023

Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)

Recruiting
  • Breast Cancer
  • Patritumab deruxtecan
  • +2 more
  • Barcelona, Spain
    Hospital Clinic de Barcelona
Nov 28, 2022

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Patritumab deruxtecan
  • (no location specified)
May 9, 2023

Metastatic Breast Cancer Trial in Villejuif (U3-1402)

Recruiting
  • Metastatic Breast Cancer
  • Villejuif, France
    Gustave Roussy
Jul 7, 2021

Breast Cancer Trial in Spain (U3 1402)

Recruiting
  • Breast Cancer
  • U3 1402
  • Badalona, Barcelona, Spain
  • +9 more
Apr 1, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer Trial in United States (U3-1402)

Recruiting
  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer
  • Birmingham, Alabama
  • +9 more
Jul 18, 2022

NSCLC Metastatic, NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Worldwide (Patritumab Deruxtecan (Fixed

Active, not recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • Patritumab Deruxtecan (Fixed dose)
  • Patritumab Deruxtecan (Up-Titration)
  • Gilbert, Arizona
  • +120 more
Jan 12, 2023

Metastatic Breast Cancer Trial in Japan, United States (Patritumab Deruxtecan)

Active, not recruiting
  • Metastatic Breast Cancer
  • Patritumab Deruxtecan
  • Newnan, Georgia
  • +25 more
Dec 5, 2022

Nonsquamous NSCLC, EGFR L858R, EGFR Exon 19 Deletion Trial in Worldwide (Patritumab Deruxtecan, Platinum-based chemo)

Recruiting
  • Nonsquamous Non-small Cell Lung Cancer
  • +2 more
  • Patritumab Deruxtecan
  • Platinum-based chemotherapy
  • Anchorage, Alaska
  • +182 more
Jan 17, 2023

Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

Recruiting
  • Breast Neoplasms
  • +10 more
  • Standard Therapy
  • +32 more
  • Birmingham, Alabama
  • +35 more
Nov 17, 2022

NSCLC (NSCLC) Trial in Worldwide (U3-1402 (FL-DP), U3-1402 (CTM-1 Lyo-DP), U3-1402 (CTM-3 Lyo-DP))

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • U3-1402 (FL-DP)
  • +2 more
  • Duarte, California
  • +21 more
Jul 5, 2022

Metastatic Colorectal Cancer Trial in Worldwide (U3-1402)

Terminated
  • Metastatic Colorectal Cancer
  • Fayetteville, Arkansas
  • +45 more
Apr 14, 2022

Osteosarcoma, Recurrent Osteosarcoma Trial in United States (Trastuzumab Deruxtecan)

Suspended
  • Osteosarcoma
  • Recurrent Osteosarcoma
  • Trastuzumab Deruxtecan
  • Birmingham, Alabama
  • +27 more
Oct 21, 2022

Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)

Recruiting
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
  • Biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jan 25, 2023

Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

Not yet recruiting
  • Invasive Breast Cancer
  • +4 more
  • Boston, Massachusetts
  • +1 more
Mar 20, 2023

Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,

Recruiting
  • Early-stage Breast Cancer
  • +6 more
  • Fullerton, California
  • +8 more
Sep 19, 2022

Breast Cancer Stage IV Trial in Vienna (Datopotamab deruxtecan)

Recruiting
  • Breast Cancer Stage IV
  • Datopotamab deruxtecan
  • Vienna, Austria
    AKH Universitaetsklinikum Vienna, Department f. Internal medicin
May 19, 2023

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Breast Tumors, Breast Cancer, HER2-positive Early Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan, Paclitaxel,

Recruiting
  • Breast Neoplasms
  • +2 more
  • Trastuzumab Deruxtecan
  • +5 more
  • Springdale, Arkansas
  • +203 more
Jan 13, 2023

Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)

Not yet recruiting
  • Breast Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Dec 14, 2022

Metastatic Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Durvalumab, Paclitaxel)

Recruiting
  • Metastatic Breast Cancer
  • Trastuzumab deruxtecan
  • +4 more
  • West Hollywood, California
  • +101 more
Jan 16, 2023